Drugs /

ifosfamide

Back to Drugs List

Overview

Generic Name(s):
ifosfamide
Trade Name(s):
Ifoxan, Cyfos, Tronoxal, Ifosfamidum, Mitoxana, Ifolem, Holoxan, Ifex, Holoxane, Ifo-Cell, and Ifomida
NCI Definition [1]:
A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)

Clinical Trials

View Clinical Trials for ifosfamide

Ifosfamide has been investigated in 28 clinical trials, of which 26 are open and 2 are closed. Of the trials investigating ifosfamide, 3 are early phase 1 (3 open), 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 15 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), and 4 are phase 3 (3 open).

MS4A1 Expression, TNFRSF8 Expression, and BCR-ABL1 Fusion are the most frequent biomarker inclusion criteria for ifosfamide clinical trials.

Diffuse large B-cell lymphoma, transformed non-hodgkin lymphoma, and hodgkin lymphoma are the most common diseases being investigated in ifosfamide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ifosfamide
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ifosfamide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ifosfamide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ipp, Cyfos, Ifex, Ifosfamidum, Holoxan, Holoxane, IFO-Cell, Ifolem, Ifomida, Ifoxan, Mitoxana, Tronoxal, isosfamide, iphosphamid, ifosfamide (product), ifosfamida, isophosphamide, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2h-1,3,2-oxazaphosphorin-2-oxide, n,3-bis(2-chloroethyl)tetrahydro-2h-1,3,2-oxazaphosphorin-2-amine 2-oxide, iphosphamide, isoendoxan, seromida, ifomide, ifosfamide, z 4942, isophosphamide, 109724, ifx, z-4942, iff, iso endoxan, iso-endoxan, 2h-1,3,2-oxazaphosphorin-2-amine, n,3-bis(2-chloroethyl)tetrahydro-, 2-oxide, mjf-9325, ifo, ifosfamide, asta z 4942, asta z-4942, 3778-73-2, isofosfamide, 7887, ifosfamide (substance), mjf 9325, ifosfamide [chemical/ingredient], 2-oxo-n,3-bis-(2-chloroethyl) tetrahydro-2h-1,3,2-oxazaphosphorin- 2-amine, iphosphamide, naxamide, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorine 2-oxide
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C564
SNOMED ID [1]:
C-78007

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.